Newsfeeds - Spark Newswire

2 minute read

Eledon Pharmaceuticals Announces The First Patient Dosed In Phase 1b Trial Evaluating Tegoprubart In Kidney Transplantation

July 18, 8:01 AM

Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ:ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell

ELDN

3 minute read

The Daily Biotech Pulse: FDA Adcomm Backing For Novavax’s COVID-19 Shot, New Data On Moderna’s Omicron Vaccine, DBV Tech’s Encouraging Peanut Allergy Trial Data

By Vandana Singh

June 8, 9:07 AM

Here's a roundup of top developments in the biotech space over the last 24 hours:

APLS

1 minute read

12 Health Care Stocks Moving In Tuesday’s Pre-Market Session

By Benzinga Insights

June 7, 8:13 AM

ANAB

1 minute read

SVB Leerink Maintains Outperform on Eledon Pharma, Lowers Price Target to $26

By Benzinga Newsdesk

June 1, 8:09 AM

SVB Leerink analyst Thomas Smith maintains Eledon Pharma (NASDAQ:ELDN) with a Outperform and lowers the price target from $33 to $26.

ELDN

3 minute read

Eledon Announces Topline Results From Phase 2a Trial Of Tegoprubart; Tegoprubart Met Primary Endpoints Of Safety And Tolerability

By Bill Haddad

May 31, 6:10 AM

Tegoprubart was well-tolerated, with no drug-related serious adverse events Dose dependent target engagement was demonstrated, and ALS associated pro-inflammatory biomarkers were both observed and significantly

ELDN

6 minute read

88 Biggest Movers From Yesterday

By Lisa Levin

May 27, 3:41 AM

Gainers Creatd, Inc. (NASDAQ: CRTD) shares jumped 58.5% to close at $1.28 on Thursday. Creatd’s board approved a rights offering of up to $40 million for 20 million shares at $2 per unit.

AFRM

2 minute read

Eledon Pharmaceuticals Announces First Patient Dosed In Phase 2a Trial Evaluating Tegoprubart In IgA Nephropathy

By Bill Haddad

May 9, 8:14 AM

Initial data from open label Phase 2a study expected in late 2022 IRVINE, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN), a patient-focused clinical stage

ELDN